Kartosthera
Founded 2018 · 70 employees on LinkedIn · 2 known investors
Find your way into Kartosthera
Sign up to see every warm intro you have to Kartosthera
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kartosthera team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kartos Therapeutics develops targeted small-molecule therapeutics aimed at treating patients with solid tumors and hematological cancers. Its work centers on inhibiting the MDM2-p53 interaction as a therapeutic target in oncology.
Investors · 2
Founder mafia
3 people who came through Kartosthera went on to found or lead other companies.
Frequently asked questions
- What does Kartosthera do?
- Kartos Therapeutics develops targeted small-molecule therapeutics aimed at treating patients with solid tumors and hematological cancers. Its work centers on inhibiting the MDM2-p53 interaction as a therapeutic target in oncology.
- Who are Kartosthera's investors?
- Kartosthera's investors include OrbiMed, SR One Capital Management.





